| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1025585539 |
| P356 | DOI | 10.1007/S13300-014-0090-Y |
| P932 | PMC publication ID | 4269640 |
| P698 | PubMed publication ID | 25502227 |
| P5875 | ResearchGate publication ID | 269712068 |
| P2093 | author name string | Susan Grandy | |
| Angelo Del Parigi | |||
| Jennifer Sugg | |||
| Sarah Bujac | |||
| Tom Liptrot | |||
| Anne-Marie Boothman | |||
| Chris Chamberlain | |||
| Martin Karpefors | |||
| P2860 | cites work | Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. | Q51332473 |
| Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range. | Q51354355 | ||
| Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. | Q51359456 | ||
| Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. | Q51372081 | ||
| Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | Q57412648 | ||
| Greedy function approximation: A gradient boosting machine | Q57532752 | ||
| The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes | Q82359377 | ||
| Pharmacogenetics, pharmacogenomics, and individualized medicine | Q23919667 | ||
| Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial | Q34153496 | ||
| Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial | Q34593046 | ||
| Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial | Q35179843 | ||
| Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy | Q36047253 | ||
| Predictive models for type 2 diabetes onset in middle-aged subjects with the metabolic syndrome | Q37028898 | ||
| Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes | Q37139427 | ||
| Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics | Q37276490 | ||
| Glucose control by the kidney: an emerging target in diabetes | Q37424426 | ||
| Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus | Q37960123 | ||
| Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial | Q42977455 | ||
| Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin | Q44653784 | ||
| Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial | Q46595958 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P304 | page(s) | 471-482 | |
| P577 | publication date | 2014-12-12 | |
| P1433 | published in | Diabetes Therapy | Q26853803 |
| P1476 | title | Patient Characteristics are not Associated with Clinically Important Differential Response to Dapagliflozin: a Staged Analysis of Phase 3 Data | |
| P478 | volume | 5 |
| Q39707501 | Baseline factors associated with glycaemic response to treatment with once-weekly dulaglutide in patients with type 2 diabetes |
| Q64999166 | Feature Selection in Predictive Modeling: A Systematic Study on Drug Response Heterogeneity for Type II Diabetic Patients. |
| Q64929185 | Letter: Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors (Diabetes Metab J 2019;43:158-73). |
| Q31157922 | Machine Learning and Data Mining Methods in Diabetes Research |
| Q48131390 | Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-Term Glycemic Response to DPP-4 Inhibitor Therapy. |
| Q64230805 | Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors |
| Q98778627 | Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus |
Search more.